Odyssey Health Inc
For the period ended Oct 31, 2024. Filed Dec 16, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Oct 31, 2024 · Filed Dec 16, 2024
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| For the Three Months Ended October 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(1,018,906) | $(538,035) |
| Adjustments to reconcile net loss to net cash flows used in operating activities: | ||
| Amortization | – | 944 |
| Stock-based compensation | 60,487 | 322,728 |
| Financing costs paid via issuance of common stock | – | 1,750 |
| Amortization of debt discount and closing costs | 19,801 | 131,662 |
| Allowance for research and development rebate due | 22,625 | – |
| Unrealized losses on investment | 370,698 | – |
| Changes in operating assets and liabilities: | ||
| (Increase) decrease in prepaid expenses and other current assets | (96,736) | 18,297 |
| Increase in research and development rebate due | – | (14,470) |
| Increase in accounts payable | 181,743 | 53,787 |
| Increase (decrease) in accrued wages | 163,495 | (63,733) |
| Increase in accrued interest | 48,279 | 27,164 |
| Net cash used in operating activities | (248,514) | (59,907) |
| Cash flows from financing activities: | ||
| Proceeds from notes payable | 300,000 | 350,000 |
| Principal and interest payments made on notes payable | – | (174,896) |
| Proceeds from equity financing | – | 45,820 |
| Net cash provided by financing activities | 300,000 | 220,924 |
| Increase in cash and cash equivalents | 51,486 | 161,017 |
| Cash and cash equivalents: | ||
| Beginning of period | 2,379 | 36,865 |
| End of period | $53,865 | $197,882 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $705 | $549 |
| Supplemental disclosure of non-cash information: | ||
| Warrants issued in connection with debt financing | $13,343 | $28,448 |
| Return of shares | – | 100 |
| Shares issued for exercised warrant | – | 1,610 |
| Debt principal, interest and fees converted to common stock | – | 76,945 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.